FK962 NEW
| Price | $31 | $47 | $93 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-08-08 |
Product Details
| Product Name: FK962 | CAS No.: 283167-06-6 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2026/08/08 |
Product Introduction
Bioactivity
| Name | FK962 |
| Description | FK962 is an somatostatin release enhancer , exerts cognitive-enhancing actions. |
| Cell Research | Dissociated, cultured trigeminal ganglion cells, containing neuronal and Schwann cells were cultured for 48 h with or without FK962. Neuronal elongation was evaluated by immunostaining with a neurofilament-specific antibody. Culture with or without GDNF, or with antibody against GDNF, was used to determine the role of GDNF in FK962-induced neurite elongation[1]. |
| In vitro | FK962?or GDNF were found to significantly induce neurite elongation. The GDNF antibody significantly inhibited elongation induced by?FK962[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (3.78 mM), Sonication is recommended. DMSO : 9 mg/mL (34.05 mM), Sonication is recommended. |
| Keywords | Somatostatin release | somatostatin | Inhibitor | inhibit | FK-962 | FK962 | FK 962 | cognitive | Alzheimer |
| Inhibitors Related | 2-Aminoethanethiol | Octreotide Acetate | Octreotide | AGI-43192 | BIM-23190 aceate | Lanreotide acetate | L-797,591 hydrochloride | [Tyr3]Octreotate | L-796,778 | CYN 154806 TFA | Cortistatin-14 acetate | Somatostatin acetate |
| Related Compound Libraries | Bioactive Compounds Library Max | Failed Clinical Trials Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-08-07 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY